WCBA
BMY icon

Weaver C. Barksdale & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
18,720
-38
-0.2% -$2.18K 0.97% 56
2026
Q1 		$1.14M Sell
18,758
-619
-3% -$36.1K 1.08% 55
2025
Q4 		$1.05M Sell
19,377
-3,786
-16% -$182K 1.1% 52
2025
Q3 		$1.04M Sell
23,163
-2,190
-9% -$102K 1.01% 53
2025
Q2 		$1.17M Sell
25,353
-278
-1% -$13.6K 1.12% 50
2025
Q1 		$1.56M Sell
25,631
-870
-3% -$50.7K 1.5% 39
2024
Q4 		$1.5M Buy
26,501
+6,921
+35% +$387K 1.44% 41
2024
Q3 		$1.01M Sell
19,580
-1,038
-5% -$48.7K 0.91% 56
2024
Q2 		$856K Sell
20,618
-503
-2% -$22.5K 0.81% 60
2024
Q1 		$1.14M Sell
21,121
-248
-1% -$12.6K 1.05% 54
2023
Q4 		$1.1M Sell
21,369
-7,291
-25% -$383K 1.07% 53
2023
Q3 		$1.66M Buy
28,660
+4,149
+17% +$254K 1.42% 43
2023
Q2 		$1.57M Sell
24,511
-1,693
-6% -$114K 1.55% 43
2023
Q1 		$1.82M Buy
26,204
+3,252
+14% +$229K 1.7% 32
2022
Q4 		$1.65M Buy
22,952
+643
+3% +$48.5K 1.46% 44
2022
Q3 		$1.59M Sell
22,309
-881
-4% -$63.9K 1.59% 34
2022
Q2 		$1.79M Buy
23,190
+212
+0.9% +$16.1K 1.66% 34
2022
Q1 		$1.68M Buy
22,978
+349
+2% +$23.4K 1.49% 43
2021
Q4 		$1.41M Buy
+22,629
New +$1.33M 1.28% 53

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Weaver C. Barksdale & Associates's BMY Position: Q2 2026 in Review

Weaver C. Barksdale & Associates reduced its Bristol-Myers Squibb (BMY) stake by 0.2% in Q2 2026, selling an estimated $2.18K and leaving 18,720 shares worth $1.08M. The position accounts for 0.97% of the portfolio, ranked #56.

Weaver C. Barksdale & Associates first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.82M in Q1 2023. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Weaver C. Barksdale & Associates held 18,720 shares of Bristol-Myers Squibb worth $1.08M as of Q2 2026.
  • Weaver C. Barksdale & Associates sold 38 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.18K.
  • Bristol-Myers Squibb made up 0.97% of Weaver C. Barksdale & Associates's portfolio in Q2 2026, its #56 holding.
  • Weaver C. Barksdale & Associates first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
  • Weaver C. Barksdale & Associates's Bristol-Myers Squibb position peaked at $1.82M in Q1 2023.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.